Race, sex, drug use, and progression of human immunodeficiency virus disease

New England Journal of Medicine

Volumn 333, Issue 12, 1995, Pages 751-756

  Chaisson, Richard E ^a   Keruly, Jeanne C ^a   Moore, Richard D ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ZIDOVUDINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL FEATURE; DRUG ABUSE; FEMALE; HEALTH CARE UTILIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INFECTION RESISTANCE; MAJOR CLINICAL STUDY; MALE; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; RACE DIFFERENCE; RISK ASSESSMENT; SEX DIFFERENCE; SOCIOECONOMICS; SURVIVAL RATE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; ADULT; AGE FACTORS; AGED; CD4 LYMPHOCYTE COUNT; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMAN; MALE; MIDDLE AGE; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SEX FACTORS; SOCIOECONOMIC FACTORS; SUBSTANCE ABUSE, INTRAVENOUS; SUPPORT, U.S. GOV'T, P.H.S.; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 0029094558     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199509213331202     Document Type: Article

References (34)

1. Selik RM, Chu SY, Buehler JW HIV infection as leading cause of death among young adults in US cities and states. JAMA 1993; 269: 2991-2994 [Erratum, JAMA 1993;270:710.]
2. AIDS among racial/ethnic minorities -- United States, 1993. MMWR Morb Mortal Wkly Rep 1994; 43: 644-655
3. Update: AIDS among women -- United States, 1994. MMWR Morb Mortal Wkly Rep 1995; 44: 81-84
4. Melnick SL, Sherer R, Louis TA, Survival and disease progression according to gender of patients with HIV infection: the Terry Beirn Community Programs for Clinical Research on AIDS. JAMA 1994; 272: 1915-1921
5. Lemp GF, Hirozawa AM, Cohen JB, Derish PA, McKinney KC, Hernandez SR Survival for women and men with AIDS. J Infect Dis 1992; 166: 74-79
6. Rothenberg R, Woelfel M, Stoneburner R, Milberg J, Parker R, Truman B Survival with the acquired immunodeficiency syndrome: experience with 5833 cases in New York City. N Engl J Med 1987; 317: 1297-1302
7. Fischl MA, Richman DD, Grieco MH, The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebo-controlled trial. N Engl J Med 1987; 317: 185-191
8. Graham NM, Zeger SL, Park LP, The effects on survival of early treatment of human immunodeficiency virus infection. N Engl J Med 1992; 326: 1037-1042
9. Chaisson RE, Keruly J, Richman DD, Moore RD Pneumocystis prophylaxis and survival in patients with advanced human immunodeficiency virus infection treated with zidovudine. Arch Intern Med 1992; 152: 2009-2013
10. Moore RD, Hidalgo J, Sugland BW, Chaisson RE Zidovudine and the natural history of the acquired immunodeficiency syndrome. N Engl J Med 1991; 324: 1412-1416
11. Chaisson RE, Fuchs E, Stanton D, Racial heterogeneity of HIV antigenemia in people with HIV infection. AIDS 1991; 5: 177-180
12. von Overbeck J, Egger M, Smith GD, Survival in HIV infection: do sex and category of transmission matter? AIDS 1994; 8: 1307-1313
13. Klein MR, Keet IP, D'Amaro J, Associations between HLA frequencies and pathogenic features of human immunodeficiency virus type 1 infection in seroconverters from the Amsterdam cohort of homosexual men. J Infect Dis 1994; 169: 1244-1249
14. Moore RD, Stanton DL, Gopalan R, Chaisson RE Racial differences in the use of drug therapy for HIV disease in an urban community. N Engl J Med 1994; 330: 763-768
15. Hogg RS, Strathdee SA, Craib KJP, O'Shaughnessy MV, Montaner JS, Schechter MT Lower socioeconomic status and shorter survival following HIV infection. Lancet 1994; 344: 1120-1124
16. Chaisson RE, Stanton DL, Gallant JE, Rucker S, Bartlett JG, Moore RD Impact of the 1993 revision of the AIDS case definition on the prevalence of AIDS in a clinical setting. AIDS 1993; 7: 857-862
17. —1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults MMWR Morb Mortal Wkly Rep 1992; 41: (RR-17): 1-19
18. Kaplan EL, Meier P Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481
19. Cox DR Regression models and life-tables. J R Stat Soc [B] 1972; 34: 187-220
20. Lee ET. Statistical methods for survival data analysis. 2nd ed. New York: John Wiley, 1992.
21. Friedland GH, Saltzman B, Vileno J, Freeman K, Schrager LK, Klein RS Survival differences in patients with AIDS. J Acquir Immune Defic Syndr 1991; 4: 144-153
22. Cozzi Lepri A, Pezzotti P, Dorrucci M, Phillips AN, Rezza G, Italian Seroconversion Study. HIV disease progression in 854 women and men infected through injecting drug use and heterosexual sex and followed for up to nine years from seroconversion. BMJ 1994; 309: 1537-1542
23. Stanton DL, Wu AW, Moore RD, Functional status of persons with HIV infection in an ambulatory setting. J Acquir Immune Defic Syndr 1994; 7: 1050-1056
24. Yarchoan R, Venzon DJ, Pluda JM, CD4 count and the risk for death in patients infected with HIV receiving antiretroviral therapy. Ann Intern Med 1991; 115: 184-189
25. Ehmann WC, Eyster ME, Wilson SE, Andes WA, Goedert JJ Relationship of CD4 lymphocyte counts to survival in a cohort of hemophiliacs infected with HIV. J Acquir Immune Defic Syndr 1994; 7: 1095-1098
26. Volberding PA, Lagakos SW, Grimes JM, The duration of zidovudine benefit in persons with asymptomatic HIV infection: prolonged evaluation of protocol 019 of the AIDS Clinical Trials Group. JAMA 1994; 272: 437-442
27. Lundgren JD, Phillips AN, Pedersen C, Comparison of long-term prognosis of patients with AIDS treated and not treated with zidovudine. JAMA 1994; 271: 1088-1092
28. Moore RD, Chaisson RE, Hidalgo J The efficacy of zidovudine is time limited. JAMA 1994; 272: 1001-1001
29. Concorde Coordinating Committee. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 1994; 343: 871-881
30. Moore RD, Keruly JC, Chaisson RE. Duration of the survival benefit of zidovudine in HIV infection. In: Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, Fla., October 4– 7, 1994. Washington, D.C.: American Society for Microbiology, 1994:61. abstract.
31. Osmond D, Charlebois E, Lang W, Shiboski S, Moss A Changes in AIDS survival time in two San Francisco cohorts of homosexual men, 1983 to 1993. JAMA 1994; 271: 1083-1087
32. Bacchetti P, Osmond D, Chaisson RE, Survival patterns in the first 500 patients with AIDS in San Francisco. J Infect Dis 1988; 157: 1044-1047
33. Goedert JJ, Kessler CM, Aledort LM, A prospective study of human immunodeficiency virus type 1 infection and the development of AIDS in subjects with hemophilia. N Engl J Med 1989; 321: 1141-1148
34. Turner BJ, Markson LE, McKee LJ, Houchens R, Fanning T Health care delivery, zidovudine use, and survival of women and men with AIDS. J Acquir Immune Defic Syndr 1994; 7: 1250-1262